Matches in SemOpenAlex for { <https://semopenalex.org/work/W4230242541> ?p ?o ?g. }
- W4230242541 endingPage "904" @default.
- W4230242541 startingPage "889" @default.
- W4230242541 abstract "Following the marked improvements in outcomes that have been seen with the use of targeted therapies in patients with non-small cell lung cancers where the cancers have sensitizing EGFR mutations and ALK fusions, there has been a drive to identify other targetable oncogenic drivers. This article discusses five oncogenes found in NSCLC that may be amenable to treatment (B-RAF; NTRK; RET; HER-2 and MET), and discusses the biology, demographics of patients with these tumors and present data as to efficacy and side-effects of treatment. As with EGFR and ALK driven lung cancers the demographics of patients with these tumors may vary from non-oncogenic driven lung cancer, with enrichment in lung adenocarcinoma and for RET and NTRK cancers in the non-smoker population. These abnormalities may be rare and given the increasing number of targets in NSCLC a panel approach using Next Generation Sequencing may be the optimum methodology for diagnosis; this may require dual DNA and RNA analysis to pick up rare fusions such as NTRK. Licensed treatments are available for NSCLC with B-RAF mutations or NTRK fusions with recent presentation of high response rates in agents targeting RET fusions. It has been more difficult to target tumors driven by HER-2 and MET, as the optimum biomarker/drug combination has been difficult to determine. However high response rates in NSCLC with MET exon 14 skip lesions to new METR inhibitors suggest that this may be an additional population that may benefit from targeted therapy. Overall given the rarity of these populations with the high response rates to treatment that can be seen new methods are needed to enable rapid but rigorous evaluation of novel agents under development." @default.
- W4230242541 created "2022-05-11" @default.
- W4230242541 creator A5015097709 @default.
- W4230242541 creator A5018478201 @default.
- W4230242541 creator A5082328872 @default.
- W4230242541 date "2022-01-01" @default.
- W4230242541 modified "2023-10-16" @default.
- W4230242541 title "Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras)" @default.
- W4230242541 cites W1627238330 @default.
- W4230242541 cites W1846586690 @default.
- W4230242541 cites W1975784282 @default.
- W4230242541 cites W1997117729 @default.
- W4230242541 cites W2007764966 @default.
- W4230242541 cites W2096735709 @default.
- W4230242541 cites W2106116393 @default.
- W4230242541 cites W2107562400 @default.
- W4230242541 cites W2111580893 @default.
- W4230242541 cites W2111842868 @default.
- W4230242541 cites W2112854176 @default.
- W4230242541 cites W2124662474 @default.
- W4230242541 cites W2140340375 @default.
- W4230242541 cites W2144187284 @default.
- W4230242541 cites W2146448515 @default.
- W4230242541 cites W2159192794 @default.
- W4230242541 cites W2159426719 @default.
- W4230242541 cites W2160304102 @default.
- W4230242541 cites W2163188200 @default.
- W4230242541 cites W2166559064 @default.
- W4230242541 cites W2168404690 @default.
- W4230242541 cites W2169624569 @default.
- W4230242541 cites W2175694606 @default.
- W4230242541 cites W2230948985 @default.
- W4230242541 cites W2239287815 @default.
- W4230242541 cites W2272081149 @default.
- W4230242541 cites W2335671095 @default.
- W4230242541 cites W2401709539 @default.
- W4230242541 cites W2409383155 @default.
- W4230242541 cites W2439107762 @default.
- W4230242541 cites W2466657922 @default.
- W4230242541 cites W2501877819 @default.
- W4230242541 cites W2507654187 @default.
- W4230242541 cites W2530716940 @default.
- W4230242541 cites W2562169753 @default.
- W4230242541 cites W2566209015 @default.
- W4230242541 cites W2600348349 @default.
- W4230242541 cites W2605109438 @default.
- W4230242541 cites W2611270905 @default.
- W4230242541 cites W2613355447 @default.
- W4230242541 cites W2726405642 @default.
- W4230242541 cites W2735084022 @default.
- W4230242541 cites W2740630940 @default.
- W4230242541 cites W2762653748 @default.
- W4230242541 cites W2767597066 @default.
- W4230242541 cites W2783112448 @default.
- W4230242541 cites W2784203648 @default.
- W4230242541 cites W2785610956 @default.
- W4230242541 cites W2790254562 @default.
- W4230242541 cites W2794839416 @default.
- W4230242541 cites W2795736967 @default.
- W4230242541 cites W2797639111 @default.
- W4230242541 cites W2799310318 @default.
- W4230242541 cites W2800809626 @default.
- W4230242541 cites W2825280821 @default.
- W4230242541 cites W2842842413 @default.
- W4230242541 cites W2887029617 @default.
- W4230242541 cites W2889373434 @default.
- W4230242541 cites W2889957730 @default.
- W4230242541 cites W2891423992 @default.
- W4230242541 cites W2894066036 @default.
- W4230242541 cites W2896424462 @default.
- W4230242541 cites W2898537638 @default.
- W4230242541 cites W2907907709 @default.
- W4230242541 cites W2913258427 @default.
- W4230242541 cites W2915968104 @default.
- W4230242541 cites W2940163088 @default.
- W4230242541 cites W2944120833 @default.
- W4230242541 cites W2946166987 @default.
- W4230242541 cites W2947129619 @default.
- W4230242541 cites W2947479209 @default.
- W4230242541 cites W2947738455 @default.
- W4230242541 cites W2947852198 @default.
- W4230242541 cites W2951301251 @default.
- W4230242541 cites W2953456310 @default.
- W4230242541 cites W2954589648 @default.
- W4230242541 cites W2954952522 @default.
- W4230242541 cites W2965810912 @default.
- W4230242541 cites W2967992516 @default.
- W4230242541 cites W2970331918 @default.
- W4230242541 cites W2973058706 @default.
- W4230242541 cites W2977150410 @default.
- W4230242541 cites W2977889895 @default.
- W4230242541 cites W2978886033 @default.
- W4230242541 cites W2979362143 @default.
- W4230242541 cites W2981697998 @default.
- W4230242541 cites W3000668520 @default.
- W4230242541 cites W3164126191 @default.
- W4230242541 doi "https://doi.org/10.1016/b978-0-08-102723-3.00002-0" @default.
- W4230242541 hasPublicationYear "2022" @default.